NassifElise Profile Banner
Elise Nassif Haddad Profile
Elise Nassif Haddad

@NassifElise

Followers
649
Following
3K
Media
54
Statuses
988

Assistant Professor, Sarcoma Medical Oncology @MDAndersonNews . Views are mine. 🇫🇷

Houston, TX
Joined January 2019
Don't wanna be here? Send us removal request.
@RyanDenu
Ryan Denu, MD, PhD
7 days
Missing @bvantine1 at @ctosociety #ctos2025 He was always a great advocate for young people and especially aspiring physician scientists like me.
3
3
37
@PestanaRC
Roberto Pestana, MD, PhD
7 days
Amazing to hear from Dr Bob Benjamin, a sarcoma pioneer, on the history of #CTOS #CTOS2025
0
7
24
@NassifElise
Elise Nassif Haddad
5 days
Our two superstar awardees this year! So well deserved!! Love seeing you together, great science to come from both your labs! #ctos2025
@RyanDenu
Ryan Denu, MD, PhD
7 days
Congrats on your National LMS Foundation award, @priyachudasama5 #ctos2025
2
1
12
@RyanDenu
Ryan Denu, MD, PhD
7 days
Congrats on your National LMS Foundation award, @priyachudasama5 #ctos2025
4
5
31
@NassifElise
Elise Nassif Haddad
5 days
So happy that our new superstar ⭐️🌟 colleague Carlos Torrado joined our Sarcoma Medical Oncology at @MDAndersonNews Be ready to see him become a leading clinical investigator in our field #CTOS2025 Welcome to the team Carlos!!
@CarlosTorradoMD
Carlos Torrado
6 days
Honored to share our Phase 1/2 data from MD Anderson at #CTOS2025 today 📊 • DR5 agonists demonstrated improved PFS compared with other therapies📈 • Stable disease with any tumor reduction (SD-ATR) was associated with improved PFS and OS and may be a meaningful surrogate
0
1
12
@HannahRAbrams
Hannah Abrams
6 days
.@RobinL_Jones @royalmarsden presenting ChonDRAgon PhII registrational study of Ozekibart in conventional #chondrosarcoma #CTOS2025 - No approved systemic therapies - mPFS 5.5 mo, with 21.7% w/o prog @ 12 mo - Activity in both IDH-WT & mut - TRAE incl ~13% fatigue, ~6% hepatitis
1
10
24
@PestanaRC
Roberto Pestana, MD, PhD
7 days
#CTOS 2025 started paying respects to the great Dr. Brian Van Tine, who unfortunately left us way too early. Dr. Van Tine was always incredibly kind to me and all in my team and helped my career in many ways
0
5
19
@wagsmd
Michael Wagner
6 days
Tumor reduction with a TEAD inhibitor for #EHE. Exciting early data from #sarcoma @DanaFarber superstar Dr Candace Haddox #CTOS2025
0
3
21
@wagsmd
Michael Wagner
7 days
Micvotabart pelidotin with some encouraging activity in hard to treat sarcomas. Strong Boston representation on the podium.💪🏻☘️ #CTOS2025
0
7
22
@FadiHaddad_MD
Fadi Haddad, MD
13 days
Off to Charleston for the weekend ✈️ Lanes at #IAH airport in #Houston were very reasonable, waiting time 25 minutes on Friday afternoon, flight delayed by 20 minutes. Overall way better than what we hear in the news 👍
2
1
61
@FadiHaddad_MD
Fadi Haddad, MD
13 days
🥇So proud of @NassifElise for all the Research & Clinical work 📄 she's doing at @MDAndersonNews to improve the outcome of #sarcoma patients around the 🌎 #leiomyosarcoma #rarecancer #endcancer #sarcsm https://t.co/wcftMXYC1N
2
2
16
@ctosociety
CTOS
24 days
#CTOS2025 is not only about great science, it's also a perfect opportunity for mentorship for trainees and young fellows! Don't miss the 🌅 Sunrise Mentorship Session on Nov 13, 7.00 am ( breakfast and coffee will be served ☕)! Check topics and mentors 🧑‍🏫on the graphic⬇️
2
18
35
@DavidHongMD
David S. Hong MD
26 days
Stephane Champiat! The Champion! @MDAndersonNews, #Targets25 !
@AACR
AACR
27 days
Cancer Vaccines: Patrick Ott, Vinod P. Balachandran, Stephane Champiat, and June-Young Koh addressed this topic in a session at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. #Targets25 @TheVinodLab @champiatMD
1
2
16
@NassifElise
Elise Nassif Haddad
1 month
The best 😍
@FadiHaddad_MD
Fadi Haddad, MD
1 month
Data from our study presented at #ESMO25 👉 2L therapy after failure of 1L 2G-TKIs in #CML 👫 276 patients 🔸Treatment switch due to side effects and/or resistance 🔸~60% response in patients with resistance 🔸3G-TKIs > 2G-TKIs #leusm #leukemia @OncoAlert @MDAndersonNews
1
0
2
@DavidHongMD
David S. Hong MD
1 month
Always so funny how you end up seeing your colleagues at meetings more than at home! @ANaing @MDAndersonNews #ESMO25
2
2
21
@FadiHaddad_MD
Fadi Haddad, MD
1 month
Data presented at #ESMO25 by Dr Mika Kontro on the Macrophage reprogrammer #bexmarilimab plus azacitidine in myelodysplastic syndrome (BEXMAB) @myESMO @OncoAlert @Daver_Leukemia @Dr_AmerZeidan
1
14
38
@FadiHaddad_MD
Fadi Haddad, MD
1 month
Always good to see you my friend 😊 @weoncologists @OncoAlert #ESMO25
0
5
16
@GladdyLab
Gladdy Lab
1 month
wonderful agenda for the #leiomysarcoma community in berlin🇩🇪 time to work on harmonized af lms care and future directions ⁦@ctosociety
0
7
20
@FadiHaddad_MD
Fadi Haddad, MD
1 month
Join me at #ESMO25 Berlin 🇩🇪 on Sunday October 19 where I will presenting our data 📈 on second line treatment after failure of frontline 2G-TKIs in chronic myeloid #leukemia #CML @OncoAlert @MDAndersonNews
4
6
36
@NassifElise
Elise Nassif Haddad
2 months
Help me #EndCancer #EndSarcoma I am raising money to give sarcoma the boot once and for all. Please consider donating to support my efforts. Your donation (100%!) helps fund Groundbreaking research that will save lives around the world. https://t.co/lTU9OOoBs2
mdanderson.donordrive.com
The University of Texas MD Anderson Cancer Center, the global leader in cancer care. Novel discoveries at MD Anderson pave the way for new cancer therapies, making a difference in the outcomes of...
0
0
6